Accelerate Drug Development with Praedicare's SYSTEM OF SYSTEMS (SOS) APPROACH

Revolutionizing Drug Development

Praedicare's SoS for Drug Development Approach has Transformed the Path to FDA/EMA Approval

Praedicare's revolutionary SoS approach accelerates drug development. With first-of-its kind integrated multiple wet lab systems, system of mathematical models, suite of AI tools, and clinical trial databases to give outcomes that are emergent properties that reduce timelines 2-3 times, >90% of costs, and maximize phase-by-phase success rates from preclinical phases to NDA/BLA.

Image


Reduce Drug Development costs by up to up to 90%

Image


Accelerate drug development cycle from bench to clinic by 2-3x

Image


De-risk patient's lives by reducing death and adverse events by 50%

WHY CHOOSE US

Praedicare Reduces Costs, Accelerates Development, and Enhances Patient Safety

We are dedicated to transforming healthcare through our innovative solutions. By reducing drug development costs by up to 20x, accelerating the development cycle by 2-3x, and significantly improving patient safety, Praedicare is revolutionizing the healthcare landscape. Explore our cutting-edge technologies and discover how we are reshaping the future of healthcare, one advancement at a time.

Quantify. Predict. Cure.

Integrating laboratory experiments, mathematical models, morphism mapping, and machine-learning/A.I. to predict:

  • Rates of Response in Patients

  • How Many Patients Will Respond

  • Optimal Duration of Therapy

  • Doses to Minimize Failure & Resistance

  • Personalized Therapy

Preclinical Lab & Math

Modeling Solutions

  • Will drug be efficacious in humans? If so, at what dose? -Are there potential toxicity risks that can be identified early? If so, at what dose?

  • Are there potential opportunities to improve efficacy through drug combinations? If so, what drug(s) and doses?

  • How best to align our regulatory strategy, pre- clinical and clinical plans to mitigate risk?

  • Demonstration of commercial viability of drug to investors & partners

Helping Clients

Our predictions have been highly accurate through Phase III studies and beyond.

  • Accurately predict efficacy and toxicity signals during preclinical phase

  • Optimal drug doses for combinations using factorial design

  • Reduce drug development timelines using our quantitative forecasting

  • Data and models that we have generated has been used by clients throughout the regulatory process by international regulatory bodies

  • We can help clients identify potential collaborators and investors

Quantify. Predict. Cure.

Integrating laboratory experiments, mathematical models, morphism mapping, and machine-learning/A.I. to predict:

  • Rates of Response in Patients

  • How Many Patients Will Respond

  • Optimal Duration of Therapy

  • Doses to Minimize Failure & Resistance

  • Personalized Therapy

Preclinical Lab & Math

Modeling Solutions

  • Will drug be efficacious in humans? If so, at what dose? -Are there potential toxicity risks that can be identified early? If so, at what dose?

  • Are there potential opportunities to improve efficacy through drug combinations? If so, what drug(s) and doses?

  • How best to align our regulatory strategy, pre- clinical and clinical plans to mitigate risk?

  • Demonstration of commercial viability of drug to investors & partners

Helping Clients

Our predictions have been highly accurate through Phase III studies and beyond.

  • Accurately predict efficacy and toxicity signals during preclinical phase

  • Optimal drug doses for combinations using factorial design

  • Reduce drug development timelines using our quantitative forecasting

  • Data and models that we have generated has been used by clients throughout the regulatory process by international regulatory bodies

  • We can help clients identify potential collaborators and investors

Wet Lab Systems

Hollow-fiber models for infectious disease, oncology, immune system, and safety with 3D human organotype

models.

Math Modeling & AI Systems

Mathematical models to

predict performance in

clinical trials for clinical trial design and adaptive clinical trial design.

In Silico & Real Clinical Trial Design

Perform clinical trials and

research in North America and 28 African countries. Modeling to support clinical trials and dose selections.

Preclinical

Services

Hollow-fiber models for infectious disease, oncology, immune system, and safety with 3D human organotype

models.

Quantitative

Clinical Forecasting

Mathematical models to

predict performance in

clinical trials for clinical trial design and adaptive clinical trial design.

Clinical Trials &

Research

Perform clinical trials and

research in North America and 28 African countries. Modeling to support clinical trials and dose selections.

First-of-its-kind Systems of Systems based Drug
Development

Customized preclinical model technologies mathematically mapped to patients for quantitative prediction of patient responses, response rates, and optimal doses and toxicology with >90% accuracy.

Model Uses Include:

  • Optimized clinical trial design, including sample size and adaptive designs

  • Identify and develop biomarkers to optimize clinical trial design and provide biology-driven clinical trial therapeutic endpoints

  • Custom-made hollow fiber technology and 3D human organoids combined with advanced ‘omics, bulk and single cell sequencing for drug discovery, biomarkers, IP strengthening/submission, safety, and IND submissions.

Unique Biotech CRO for Drug Discovery, Development

& Clinical Trials

Customized preclinical model technologies mathematically mapped to patients for quantitative prediction of patient responses, response rates, and optimal doses and toxicology with >90% accuracy.

Model Uses Include:

  • Optimized clinical trial design, including sample size and adaptive designs

  • Identify and develop biomarkers to optimize clinical trial design and provide biology-driven clinical trial therapeutic endpoints

  • Custom-made hollow fiber technology and 3D human organoids combined with advanced ‘omics, bulk and single cell sequencing for drug discovery, biomarkers, IP strengthening/submission, safety, and IND submissions.

INTERESTED IN LEARNING MORE?

Contact Us Today

21

56

Number of Biopharma

Companies Worked With

Number of Projects

Worked On

INTERESTED IN LEARNING MORE?

Contact Us Today

49

Number of Biopharma

Companies Worked With

19

Number of Projects

Worked On